Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Nov 25, 2024 · Filed Nov 26, 2024
The CEO of Perspective Therapeutics paid $25K out of pocket for Perspective Therapeutics shares. 3 other people at Perspective Therapeutics bought some too, in the same month. It was the first purchase in over a year.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$25,080
Shares × reported transaction price
$25K–$100K
+11.0%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
None in 13 months of history
Confirmed open-market purchases by the same insider in the available history
4 distinct insiders in 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
This purchase equals about 1.7% of the CEO's reported total pay for fiscal 2023 ($1.46M)
Purchase value ÷ the CEO's total from the Summary Compensation Table, as tagged in the pay versus performance table of the company's proxy statement (DEF 14A), filed 2026-04-16. The proxy names this person as CEO for that year. A size comparison, not a judgement
13 days after results of Nov 12, 2024, 49 days before results of Jan 13, 2025
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
None found in footnotes
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −9.9% | +1.5% | −11.4% |
| 30 days | −22.6% | −0.6% | −21.9% |
| 90 days | −35.4% | −0.8% | −34.7% |
| 180 days | −41.8% | −1.3% | −40.5% |
| 365 days | −43.0% | +14.1% | −57.1% |
Past results only. Not a forecast.
Insider buying
Traded Dec 4, 2024 · filed 2 days later
A Perspective Therapeutics director paid $100K out of pocket for Perspective Therapeutics shares. 3 other people at Perspective Therapeutics bought some too, in the same month. It was the first purchase in over a year.
Insider buying
Traded Dec 4, 2024 · filed the same day
The CEO of Perspective Therapeutics paid $30K out of pocket for Perspective Therapeutics shares. 3 other people at Perspective Therapeutics bought some too, in the same month. Shares held went up 28% with this purchase.
Insider buying
Traded Nov 25, 2024 · filed 2 days later
The CFO of Perspective Therapeutics paid $114 out of pocket for Perspective Therapeutics shares. 3 other people at Perspective Therapeutics bought some too, in the same month. It was the first purchase in over a year.
Johan M. Spoor, CEO's past purchases, 90 days after disclosure: 3 buys, median −28.1 pts vs S&P 500, beat it 1 of 3 times. Past results, not a forecast.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
